Group items tagged

The patient monitoring devices market was worth $14.2 billion in the year 2011 and is expected to grow at a CAGR of 5.9% from 2011 to 2016 to reach $18.9 billion.

[333 Pages Report] European Injectable Drug Delivery Market report categorizes the europe market by Therapeutics [Diabetes & Oncology], by Devices [Disposables & Reusable, Fillable & Prefilled, Pen, Needle Free & Auto Injectors], Formulations [Liposomes, Microspheres, & Nanoparticles], Market & Geography

Injectable Drug Delivery Market by Formulations [Liposomes, Microspheres, & Nanoparticles], Devices [Disposables & Reusable, Fillable & Prefilled, Pen, Needle Free & Auto Injectors] & Therapeutics [Diabetes & Oncology] - Global Forecasts to 2017

[Price: $4650] [No of pages - 280 ] Browse 130 market tables and 28 figures/charts on North America Injectable Drug Delivery Market report categories North America market estimating and forecasting 2017 by Devices [Disposables & Reusable, Fillable & Prefilled, Pen, Needle Free & Auto Injectors], Formulations [Liposomes, Microspheres, & Nanoparticles], Therapeutics [Diabetes & Oncology]& Geography

Endoscopy market research report provides comprehensive analysis on global market of endoscopy by products/devices, applications and technology.

European Injectable Drug Delivery Market By Formulations [Liposomes, Microspheres, & Nanoparticles], Devices [Disposables & Reusable, Fillable & Prefilled, Pen, Needle Free & Auto Injectors] & Therapeutics [Diabetes & Oncology] - Forecasts to 2017

Injectable Drug Delivery Market by Formulations [Liposomes, Microspheres, & Nanoparticles], Devices [Disposables & Reusable, Fillable & Prefilled, Pen, Needle Free & Auto Injectors] & Therapeutics [Diabetes & Oncology] - Global Forecasts to 2017

North America Injectables Drug Delivery Market- by Formulations [Liposomes, Microspheres, & Nanoparticles], Devices [Disposables & Reusable, Fillable & Prefilled, Pen, Needle Free & Auto Injectors] & Therapeutics [Diabetes & Oncology] - Forecasts to 2017

The product segments in the medical aesthetics market are dominated by various players, depending on their core competencies. In 2014, Cynosure Inc., Syneron Medical Ltd., Solta Medical, Inc., ZELTIQ Aesthetics, Inc., Lumenis Ltd., and PhotoMedex, Inc. were the leading companies in the global medical aesthetics laser and energy devices market. Moreover, in 2014, Allergan, Inc., Galderma S.A., and Merz Aesthetics, Inc. were the leading players in the global facial aesthetics market. The breast implants market was dominated by Allergan, Inc. and Mentor Corporation in 2014.

Hearing aids accessories, such as protective cases, are a must since it can be so costly to repair these precision instruments.Of course, you definitely need to buy a quality accessory to go with your device- a decent case can mean the difference between a broken hearing aid and a "whew" moment.

Market Overview: Skin substitutes are natural, synthetic or biosynthetic materials, used to cover large wounds to restore at least some of the functions of the skin. Skin substitutes provides temporary or permanent wound closure and protect the wound from infection, further damage and water loss, and reduce pain. They also facilitate the growth of the normal skin over the wound. Skin substitutes provide a permanent solution and are used in the treatment of conditions like burns, trauma wounds, diabetes or venous ulcers, where skin grafts may not be possible. Market Dynamics: Rising chronic skin diseases is expected to drive the skin substitutes market. For instance, according to the global burden of disease study 2013, Skin conditions contributed around 1.79% to the global disease burden. According to the World Health Organization, about 132,000 melanoma skin cancers occur each year worldwide. Thus, the rising chronic diseases is increasing the demand for skin substitutes in the forecast period. Rising prevalence of diabetes is expected to boost the market. This is owing to the risk of developing a diabetic foot ulcer over the period of time in diabetic patients. For instance, WHO has reported that the incidence of diabetes for all age-groups worldwide was estimated to be 2.8% in 2000 and 4.4% in 2030. The total number of people with diabetes is anticipated to rise from 171 million in 2000 to 366 million in 2030. Thus, as a consequence, the prevalence of diabetes related complications are expected to increase over the forecast period. There are several limitations to the commercially available skin substitutes, like reduced vascularization, poor mechanical integrity, failure to integrate, scarring, and immune rejection. Market Segmentation: Rise in preference for acellular skin substitutes to implant-based skin surgery is expected to drive the growth of the skin substitutes market. For instance, the American Society of Plastic Surgeons in 2012, reported that

The program has improved overall performance in handling cardiopulmonary resuscitation codes, generating fast response times, reducing the frequency of equipment-related issues, improving success with first-time intubations, and enhancing communication and teamwork. This success has, in turn, improved staff satisfaction.